FindTrial
Sign In

Quality of life viral and Immunological dynamics in patients with effectively suppressed HIV who switch second or furtherline cART to a Once daily High genetic barrier Antiretroviral regimen of boosted darunavir and dolutegravir

Quality of life viral and Immunological dynamics in patients with effectively suppressed HIV who switch second or furtherline cART to a Once daily High genetic barrier Antiretroviral regimen of boosted darunavir and dolutegravir - QIOHA

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41798
Enrollment
100
Registered
2016-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hiv

Interventions

None listed

Sponsors

Onze Lieve Vrouwe Gasthuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Switch on clinical grounds to dolutegravir/ darunavir/ritonavir - Viral load

Exclusion criteria

Exclusion criteria: - Active opportunistic infections - Hepatitis B coinfection AND treatment with drugs also used in HIV treatment (lamivudine, tenofovir)

Design outcomes

Primary

MeasureTime frame
Change in quality of life (QOL)—

Secondary

MeasureTime frame
Investigation of the impact of switch to two high genetic barrier compounds on (I) residual replication (presence of plasma and intracellular HIV-RNA) (II) level of virus production from infected cells (reservoir; presence of HIV), (III) number of HIV virological failures and resistance analysis and (IV) Immunological markers (change in activation-, proliferation- and inflammation markers).—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)